白蛋白结合 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式，随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性，需干燥保存 |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
=== Dynamic catch === The above bonds involve bimolecular interactions, which arguably represents the simplest types. A new type of catch bonds emerges when trimolecular interactions are involved. In such cases, one molecule can interact with the two counter-molecules using two binding sites, either separately, i.e. one at a time in the absence of the other to form bimolecular bonds, or concurrently to form a trimolecular bond when both counter-molecules are present. An interesting finding is that even when the two bimolecular interactions behave as slip bonds, the trimolecular interaction can behave as catch bond. This new type of catch bond, which requires concurrent and cooperative binding, is termed dynamic catch.
The efficiency of removal can be optimized by treating the EPS sugars with different acids or bases before adding them to wastewater. Some contaminated soils contain high levels of polycyclic aromatic hydrocarbons (PAH); EPS from the bacterium Zoogloea sp. and the fungus Aspergillus niger, are efficient at removing these toxic compounds. EPS contain enzymes such as oxidoreductase and hydrolase, which are capable of degrading PAH. The amount of PAH degradation depends on the concentration of EPS added to the soil. This method proves to be low cost and highly efficient.
Ammunition and other resources are generally placed in locations appropriate to the environment rather than appearing as arbitrary pickups; contemporary reviewers noted that weapons, ammunition, and health supplies were integrated into the surrounding world to reinforce the game's sense of realism. The game frequently combines combat with environmental puzzles. These challenges can involve operating machinery, navigating conveyor systems, manipulating movable objects, finding alternative routes, or using environmental hazards against enemies. For example, the player can manipulate valves to release dangerous steam, while boxes and other objects can be arranged to create paths to otherwise inaccessible areas. These puzzles are generally presented as problems within the environment rather than as explicitly marked challenges, requiring the player to observe the surroundings and determine an appropriate solution. Enemy encounters are similarly integrated into the environment. The player encounters a variety of alien organisms, including headcrabs, bullsquids, Vortigaunts, and headcrab zombies, as well as human opponents such as military soldiers and Black Ops assassins. Human enemies were noted for their use of coordinated behavior and tactical responses, while different alien species possess distinct methods of attacking the player. Valve demonstrated AI features such as fear and group behavior during the game's development, contributing to encounters in which enemies could react to the player's actions rather than simply attacking from predetermined positions.
Sources: en.wikipedia.org
== Etymology == It is named for the English physician and anatomist Thomas Wharton (1614–1673) who first described it in his publication Adenographia, or "The Description of the Glands of the Entire Body", first published in 1656.
=== Uganda === Uganda has the fifth-highest sickle cell disease (SCD) burden in the world. In Uganda, social stigma exists for those with sickle cell disease because of the lack of general knowledge of the disease, notably among adolescents and young adults due to the culturally sanctioned secrecy about the disease. While most people have heard generally about the disease, a large portion of the population is relatively misinformed about how sickle cell disease is diagnosed or inherited. Those who are informed about the disease learned about it from family or friends and not from health professionals. Failure to provide the public with information about sickle cell disease results in a population with a poor understanding of the causes of the disease, symptoms, and prevention techniques. The differences, physically and socially, that arise in those with sickle cell disease, such as jaundice, stunted physical growth, and delayed sexual maturity, can also lead them to become targets of bullying, rejection, and stigma.
== Activists == Samuel Cutler Ward (1831), lobbyist known as the "King of the Lobby" Henry Bergh* (1834), founder of the American Society for the Prevention of Cruelty to Animals and the Massachusetts Society for the Prevention of Cruelty to Children Arthur B. Spingarn (1897), civil rights activist; elected president of the National Association for the Advancement of Colored People 1940–1965; namesake of the Moorland–Spingarn Research Center at Howard University George Marshall (1926), political activist and conservationist John B. Trevor Jr. (1931), director and treasurer of the Pioneer Fund David Crook (1935), British-born Communist ideologue, activist, spy, husband of Isabel Crook, professor at Beijing Foreign Studies University Robert Gnaizda (1957), lawyer, activist, and co-founder of advocacy group Greenlining Institute Morris J.
=== Growth factors and proteolytic enzymes === Chronic wounds also differ in makeup from acute wounds in that their levels of proteolytic enzymes such as elastase. and matrix metalloproteinases (MMPs) are higher, while their concentrations of growth factors such as Platelet-derived growth factor and Keratinocyte Growth Factor are lower. Since growth factors (GFs) are imperative in timely wound healing, inadequate GF levels may be an important factor in chronic wound formation. In chronic wounds, the formation and release of growth factors may be prevented, the factors may be sequestered and unable to perform their metabolic roles, or degraded in excess by cellular or bacterial proteases. Chronic wounds such as diabetic and venous ulcers are also caused by a failure of fibroblasts to produce adequate ECM proteins and by keratinocytes to epithelialize the wound. Fibroblast gene expression is different in chronic wounds than in acute wounds. Though all wounds require a certain level of elastase and proteases for proper healing, too high a concentration is damaging. Leukocytes in the wound area release elastase, which increases inflammation, destroys tissue, proteoglycans, and collagen, and damages growth factors, fibronectin, and factors that inhibit proteases. The activity of elastase is increased by human serum albumin, which is the most abundant protein found in chronic wounds. However, chronic wounds with inadequate albumin are especially unlikely to heal, so regulating the wound's levels of that protein may in the future prove helpful in healing chronic wounds.
Sources: en.wikipedia.org
=== Physical examination === Inspection of the patient's skin, particularly on the lower extremities, in conjunction with a thorough medical history, can provide valuable information regarding the possible presence of sudomotor dysfunction. Evidence of altered skin hydration, such as hyperkeratosis, excessive skin dander, rhagades, and ulcers, can be suggestive of sudomotor dysfunction. Presence of intense foot odor may be another presentation.
== Timeline and list of outbreaks == 1960: Outbreak of Turkey 'X' disease in England, and aflatoxin discovery. 1961: Identified Aspergillus flavus associated with toxicity of groundnuts. 1962: Aflatoxin B and G identified in TLC analysis. Isolation and synthesis of aflatoxins. 1963: Aflatoxin B2, G1, and G2 were identified and chemically characterized as difurocoumarin derivatives. 1965: FDA approved the first regulation on aflatoxins 30 μg/kg. 1966: Milk toxins were designated as AFM1 and AFM2, and AFM1 was detected in milk, urine, kidney, and liver. 1973 Poland: 10 died following the opening of the tomb of Casimir IV Jagiellon, which contained aflatoxin-producing molds. 2004 Kenya: acute outbreak of aflatoxicosis resulting from ingestion of contaminated maize, 125 confirmed deaths. 2005 US: Diamond Pet Foods recalled aflatoxin-contaminated pet food manufactured from corn at their facility in Gaston, South Carolina. 2009–2011 International: Commercial peanut butter, cooking oils (e.g. olive, peanut and sesame oil), and cosmetics were identified as contaminated with aflatoxin. In some instances, liquid chromatography–tandem mass spectrometry (LC–MS/MS), and other analytical methods, revealed that 48–80% of selected product samples contained detectable quantities of aflatoxin. In many of these contaminated food products, the aflatoxin exceeded the safe limits of the U.S. Food and Drug Administration (FDA) or other regulatory agencies. February–March 2013: Romania, Serbia, Croatia imported into western Europe – 2013 aflatoxin contamination. February 2013: Iowa contamination.
== History == The syndrome was first recognized in Royal Melbourne Hospital, Australia in an affected family by Denborough et al. in 1962. Denborough did much of his subsequent work on the condition at the Royal Canberra Hospital. Similar reactions were found in pigs. The efficacy of dantrolene as a treatment was discovered by South African anesthesiologist Gaisford Harrison and reported in a 1975 article published in the British Journal of Anaesthesia. After further animal studies corroborated the possible benefit from dantrolene, a 1982 study confirmed its usefulness in humans. In 1981, the Malignant Hyperthermia Association of the United States (MHAUS) hotline was established to provide telephone support to clinical teams treating patients with suspected malignant hyperthermia. The hotline became active in 1982 and since that time MHAUS has provided continuous access to board-certified anesthesiologists to assist teams in treatment.
Sir Bernard Rawdon Reilly (1 April 1937 – 24 October 1940) John Hathorn Hall (24 October 1940 – 1 January 1945) (From 2 December 1940, Sir John Hathorn Hall) Reginald Stuart Champion (1 January 1945 – 1950) (From 1 January 1946, Sir Reginald Stuart Champion) William Allmond Codrington Goode (1950 – April 1951) (Acting) Sir Tom Hickinbotham (April 1951 – 13 July 1956) Sir William Luce (13 July 1956 – 23 October 1960) Sir Charles Johnston (23 October 1960 – 18 January 1963)
==== 4.D Polysaccharide Synthase/Exporters ==== 4.D.1 The Putative Vectorial Glycosyl Polymerization (VGP) Family 4.D.2 The Glycosyl Transferase 2 (GT2) Family 4.D.3 The Glycan Glucosyl Transferase (OpgH) Family
Sources: en.wikipedia.org
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高，同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足，分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因，它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略，二者共同作用。脂肪链的疏水性还会影响组织分布，但其对总半衰期的贡献程度仍在研究之中。
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.